Inhibition of gap junctional intercellular communication by an anti-migraine agent, flunarizine
Joo Hye Yeo aff001; Eun Ju Choi aff001; Jinu Lee aff001
Authors place of work:
College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Songdogwahak-ro, Yeonsu-gu, Korea
Published in the journal:
PLoS ONE 14(9)
Gap junctions (GJs), which consist of proteins called connexins, are intercellular channels that allow the passage of ions, second messengers, and small molecules. GJs and connexins are considered as emerging therapeutic targets for various diseases. Previously, we screened numerous compounds using our recently developed iodide yellow fluorescent protein gap junctional intercellular communication (I-YFP GJIC) assay and found that flunarizine (FNZ), used for migraine prophylaxis and as an add-on therapy for epilepsy, inhibits GJIC in LN215 human glioma cells. In this study, we confirmed that FNZ inhibits GJIC using the I-YFP GJIC assay. We demonstrated that FNZ inhibits GJ activities via a mechanism that is independent of calcium channels and dopaminergic D2, histaminergic H1, or 5-HT receptors. In addition, we showed that FNZ significantly increases connexin 43 (Cx43) phosphorylation on the cell surface, but does not alter the total amount of Cx43. The beneficial effects of FNZ on migraines and epilepsy might be related to GJ inhibition.
Biology and life sciences – Biochemistry – Proteins – Post-translational modification – Phosphorylation – Luminescent proteins – Yellow fluorescent protein – Neurochemistry – Neurotransmitters – Biogenic amines – Catecholamines – Dopamine – Histamine – Hormones – Molecular biology – Molecular biology techniques – Molecular probe techniques – Immunoblotting – Neuroscience – Research and analysis methods – Medicine and health sciences – Diagnostic medicine – Signs and symptoms – Headaches – Migraine – Pathology and laboratory medicine – Pharmaceutics – Drug therapy – Receptor antagonist therapy – Calcium antagonist therapy – Physical sciences – Chemistry – Chemical compounds – Organic compounds – Amines – Iodides – Organic chemistry
Gap junctions (GJs) mediate cell-to-cell communication, known as gap junctional intercellular communication (GJIC), which enables the exchange of small molecules (< 1 kDa), including ions, metabolites, and nutrients, between the cytoplasm of adjacent cells. Six connexins constitute a connexon, which is joined to that of an adjacent cell to form a GJ . GJs or connexins play crucial roles in the development, growth control, and homeostasis of tissues and organs, as well as the pathophysiology of various diseases including cardiovascular diseases, such as hypertrophic cardiomyopathy, heart failure, and myocardial infarction ;; particular subtypes of epilepsy ; migraine with aura ; non-neoplastic liver diseases ; wound healing ; glaucoma ; non-syndromic deafness ; X-linked Charcot-Marie Tooth disease ; and oculodentodigital dysplasia (ODDD) ;. In addition, GJs and connexins have been used for toxicological assessment of carcinogens, such as polycyclic aromatic hydrocarbons, that block GJs ;. Several reports have suggested that disrupted GJIC is associated with nongenotoxic carcinogenesis ;. Therefore, there is a growing interest in developing new pharmaceuticals that can modulate GJs.
Recently, we developed a cell-based high-throughput screening (HTS)-compatible iodide yellow fluorescent protein gap junctional intercellular communication (I-YFP GJIC) assay. This I-YFP GJIC assay utilizes acceptor and donor cells that express YFPQL, an iodide-sensitive yellow fluorescent protein variant, and SLC26A4, an iodide transporter, respectively. When iodides are added to a co-culture of acceptor and donor cells, they solely enter the donor cells via SLC26A4 and migrate to the adjoining acceptor cells via the GJs. The iodides that enter the acceptor cells quench the YFP fluorescence of the acceptor cells. Thus, the YFP fluorescence quenching rates reflect GJ activities . We screened numerous compounds, including Food and Drug Administration approved drugs, using the I-YFP GJIC assay and identified flunarizine (FNZ) as a GJIC inhibitor.
FNZ is a versatile drug used for various pathological conditions because of its various pharmacological activities; it not only blocks calcium entry , but also inhibits the function of dopamine D2 , histamine H1 , and 5-HT receptors . FNZ is useful in preventing migraine attacks and is also used as an add-on treatment in drug-resistant epilepsy patients, occlusive peripheral vascular disease, and central and peripheral vertigo . A recent cohort study of migraine patients in the UK demonstrated that FNZ is generally effective for chronic migraine, thus encouraging the use of FNZ for migraines . In this report, we demonstrate FNZ-induced GJIC inhibition in LN215 human glioma cells, as well as additional data suggesting its mechanism of action.
Materials and methods
FNZ and 5-HT were purchased from Sigma-Aldrich (St. Louis, MO, USA). Histamine and dopamine were provided by Tokyo Chemical Industry (Tokyo, Japan). The calcium channel blockers, D2 antagonists, H1 blockers, and 5-HT antagonists used in this study were obtained from Spectrum collections (MicroSource Discovery Systems, New Milford, CT, USA).
Human glioma cells LN215 (a kind gift from Dr. Erwin G. Van Meir), LN215-YFP, and LN215-SLC26A4  were grown in Dulbecco's Modified Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS). FRT-Cx43  cells were cultured in a 1:1 mixture of DMEM and Ham’s F-12 medium supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% FBS. Cells were maintained in a 5% CO2/95% air and humidified environment at 37°C.
Gap-fluorescence recovery after photobleaching (FRAP) assay
FRT-Cx43 cells  were plated on a 35-mm glass-bottomed dish coated with 2% gelatin (Sigma-Aldrich) and grown to 80% confluence. Cells were treated with vehicle or drugs diluted in C-solution (10 mM HEPES [pH 7.4], 140 mM NaCl, 10 mM glucose, 5 mM KCl, 1 mM MgCl2, and 1 mM CaCl2), as indicated. Next, 10 μM calcein-AM (Sigma-Aldrich) was added to the cells followed by a further 10 min incubation. The cells were washed twice with C-solution and incubated with the same C-solution containing vehicle or drug as in the previous treatment. Cells surrounded by more than five adjoining cells were selected using an LSM 710 confocal microscope (Zeiss, Jena, Germany) and then photo-bleached for 50 s with a maximal laser. Fluorescence images were taken 50 s prior to (-50 s) and immediately after (0 s) bleaching and then at 10 s intervals for 170 s. The percentage of fluorescence recovery was calculated as follows: % fluorescence recovery = (Ft—F0) / (F-50—F0) × 100, where Ft represents the fluorescence at any time point, F-50, the fluorescence recorded 50 s prior to photobleaching, and F0, the fluorescence immediately after photobleaching.
I-YFP GJIC assay
The I-YFP GJIC assay was performed as previously described , with minor modifications. Briefly, a 1:4 mixture of LN215-YFP and LN215-SLC26A4 cells was plated on a 96-well plate at a density of 20,000 cells/well and incubated for 24 h. Culture media were aspirated and cells were washed twice with 200 μL of C-solution. Next, the cells were treated with vehicle or chemicals diluted in 100 μL C-solution and further incubated for the indicated period. The 96-well plate containing the cells was placed into a POLARstar microplate reader (BMG Labtech, Ortenberg, Germany). An equal volume of I-solution (10 mM HEPES [pH 7.4], 140 mM NaI, 10 mM glucose, 5 mM KCl, 1 mM MgCl2, and 1 mM CaCl2) was injected into each well at 1 s after each measurement was started at a rate of 135 μL/s using the machine-equipped automated injector. Fluorescence was measured for 20 s at 0.4 s intervals in kinetic mode using a 485 nm excitation/520 nm emission filter. The percentage (%) of YFP quenching and GJIC activity were calculated as follows:
Analysis of Cx43 on the cell surface
In situ biotinylation was conducted to analyze Cx43 located on the plasma membrane by immunoblotting. One day prior to biotinylation, LN215 cells were seeded on 100-mm plates to reach 100% confluence in 24 h and then treated with chemicals as indicated. Next, cells were placed on ice and washed three times with cold phosphate buffered saline (PBS) containing 100 mg/L CaCl2 and 100 mg/L MgCl2 (PBS-C/M). Cell surface proteins were biotinylated by adding 4 mL of 0.5 mg/mL Sulfo-NHS-Biotin (Thermo Fisher Scientific, Rockford, IL, USA) in PBS-C/M, followed by incubation with gentle rocking for 30 min. Following a wash with ice-cold PBS-C/M, 4 mL of 100 mM glycine in PBS-C/M were added to the cells for 20 min with gentle rocking to quench the remaining Sulfo-NHS-Biotin and the cells were then washed three times. The cells were lysed with cold PBS-Triton lysis buffer containing 0.6× PBS, 1% Triton X-100, 1× cOmplete Protease Inhibitor Cocktail (Roche, Basel, Switzerland) with ethylenediaminetetraacetic acid (EDTA), and 1× Halt Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). The lysates were clarified by centrifugation at 15,000 × g at 4°C for 10 min. Protein concentration was measured using a bicinchoninic acid (BCA) assay. To collect biotinylated proteins, 1 mg of protein was incubated with 20 μL of NeutrAvidin agarose resin (Thermo Fisher Scientific) at 4°C with gentle rotating overnight. The agarose resin was pelleted by centrifugation at 15,000 × g for 30 s and then washed five times with lysis buffer. Biotinylated proteins for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) were eluted by incubating the pelleted resin in 50 μL of 2× Laemmli sample buffer at 37°C for 10 min.
The biotinylated protein samples extracted from 1 mg of protein lysate were separated by 8% SDS-PAGE and transferred onto nitrocellulose membranes (Whatman, Dassel, Germany) for immunoblotting. The membranes were blocked with 5% bovine serum albumin (BSA) in PBS containing 0.05% Tween 20 (PBST) for Na+-K+ ATPase, or with 5% skim milk in PBST for Cx43 and actin. Primary antibodies (anti-Na+-K+ ATPase Ab [ab7671; Abcam, Cambridge, UK], anti-Cx43 Ab [C13720; BD BioSciences, San Diego, CA, USA], and anti-actin Ab [sc-1651; Santa Cruz Biotechnology, Santa Cruz, CA, USA]) were used at a 1:1,000 dilution in the corresponding blocking solutions. The secondary anti-Mouse Ab or anti-Goat Ab conjugated with HRP (PI2000; Vector Laboratories, Burlingame, CA, USA) was used at a 1:5,000 dilution in PBST + 5% BSA or skim milk. Immunoblot images generated with enhanced chemiluminescence (ECL) solution (Thermo Fisher Scientific) were captured using a Fusion Solo 4M (Vilber Lourmat, Eberhardzell, Germany). The band intensities were analyzed using ImageJ software. The degree of phosphorylation was calculated based on the ratio of the intensity of the phosphorylated bands (P1 and P2) relative to that of the non-phosphorylated bands (P0). The total amount of Cx43 on the membrane was calculated based on the intensities of the total Cx43 bands (P0 + P1 + P2) divided by those of the Na+-K+ ATPase bands. Minimal cytosolic protein contamination in the cell surface samples was confirmed by the absence of actin.
Assessing the change in [Ca2+]in following FNZ treatment
LN215 cells were cultured in 96-well plates to reach 90% confluence. The Fluo4 NW Calcium Assay Kit (F36206, Thermo Fisher Scientific) was used to monitor [Ca2+]in according to the manufacturer’s instructions. Growth media were removed and cells were incubated with 100 μL of the dye loading solution for 45 min at 37°C. Next, the cells were treated with vehicle or 50 μM FNZ and Fluo4 fluorescence was measured prior to and every 30 min after treatment with vehicle or FNZ for 240 min using a POLARstar microplate reader (BMG Labtech). As the Fluo4 dye loaded in the cells is released into culture medium at a millimolar Ca2+ concentration, Fluo4 fluorescence distinctly increases following 4 h of incubation. Thus, the Fluo4 fluorescence of FNZ-treated cells was normalized to that of vehicle-treated cells for each time point. To assess the rapid effect of FNZ on [Ca2+]in, the 96-well plate with cells was placed into a POLARstar microplate reader (BMG Labtech) after dye loading, as described above. Vehicle, 50 μM FNZ, or vehicle together with 100 μM ATP were added to each well using the automatic injector of the microplate reader and the Fluo4 fluorescence of each well was measured every 0.5 s for 100 s. The Fluo4 fluorescence of each group measured after the injection was normalized to that of the corresponding group at the time of injection initiation (0 s) and plotted as graphs.
Replicate experiments were conducted at least three times and data are expressed as mean ± standard deviation (SD).
Statistical significance was assessed by Student’s t-test using SSPS software.
GJIC inhibition by FNZ
To assess the effect of FNZ on GJIC activity, we conducted an I-YFP GJIC assay in LN215 cells. GJIC inhibition was observed in cells treated with 50 μM FNZ for 4 h or 30 μM carbenoxolone (CBX), a well-known GJ blocker (used as the positive control), for 10 min, but not in the vehicle-treated control group (Fig 1A). The percentage of YFP fluorescence in vehicle-treated cells was quenched by 27.4% (63.4 ± 7.7% of the initial value), whereas that in FNZ- or CBX-treated cells was only quenched by ~3% (97.0 ± 0.6 or 96.8 ± 3.9% of the initial value, respectively) after 20 s (Fig 1A). Original representative images of cells in Fig 1A at different time points with different treatments are presented in Fig 1B. Since compounds that inhibit SLC26A can exhibit artifactual GJIC inhibition, we examined whether FNZ inhibits SLC26A4. The iodide uptake via SLC26A4 was not inhibited by FNZ (S1 Fig).
GJIC inhibition by FNZ was also observed using the gap-FRAP assay, a commonly used GJIC assay, in FRT-Cx43 cells. The percentage of fluorescence recovery after bleaching decreased in cells treated with 30 μM FNZ (31.7 ± 4.3%) or 100 μM FNZ (13.4 ± 4.3%) for 4 h compared with cells treated with the vehicle (58.8 ± 0.9%) for 4 h (Fig 2A). Representative images of the gap-FRAP assay are presented in Fig 2B.
Time course and dose-response relationship of FNZ-induced GJIC inhibition
To elucidate the underlying mechanism of GJIC inhibition by FNZ, we first attempted to determine the appropriate treatment conditions in terms of duration and concentration. As shown in Fig 3A, FNZ treatment reduced GJIC activities in a time-dependent manner (66.3 ± 5.1% at 30 min, 55.7 ± 3.7% at 1 h, 26.9 ± 1.1% at 2 h, and 6.7 ± 0.8% at 4 h) compared with the group treated with vehicle for 30 min. Next, I-YFP GJIC assays were conducted following treatment with various concentrations of FNZ for the same time (4 h). As shown in Fig 3B, FNZ inhibited GJIC in a dose-dependent manner (5 μM, 106.0 ± 7.2%; 10 μM, 100.5 ± 6.9%; 20 μM, 63.3 ± 2.2%; and 50 μM, 8.4 ± 1.7%). Collectively, we concluded that treating LN215 cells with 50 μM FNZ for 4 h constitutes a potent condition for GJIC inhibition; thus, most subsequent experiments were conducted under this condition.
Slow reversal of FNZ-induced GJIC inhibition
To examine how rapidly FNZ-mediated GJIC inhibition is reversed following FNZ removal, I-YFP GJIC assays were conducted in LN215 cells treated with vehicle or 50 μM FNZ for 4 h, or 30 μM CBX for 10 min, and then washed. GJIC activities were measured prior to washing or 30, 60, 120, or 240 min after washing. As shown in Fig 4, GJIC activities were slowly restored in the FNZ-treated group (10.1 ± 12.4% for no wash, 40.2 ± 6.8% at 30 min, 75.4 ± 1.3% at 60 min, 92.7 ± 1.4% at 120 min, and 99.9 ± 1.2% at 240 min after washing) compared with the CBX-treated group (21.7 ± 9.5% for no wash, 98.3 ± 1.2% at 30 min, 102.4 ± 0.9% at 60 min, 106.5 ± 1.5% at 120 min, and 103.1 ± 1.5% at 240 min after washing).
Effect of FNZ treatment on cell surface expression of Cx43
Cx43 is the major connexin in LN215 human glioma cells . As only connexins located on the cell surface, not in the cytosol, form GJs, Cx43 expression on the plasma membrane, which is more relevant to GJ activity, was analyzed by cell surface biotinylation followed by immunoblotting using an anti-Cx43 antibody. Whole cell lysates were also analyzed by immunoblotting. An anti-Na+-K+ ATPase antibody was used as the loading control and an anti-actin antibody was used to check for cytoplasmic protein contamination in the biotinylated samples. Representative immunoblot images are presented in Fig 5A (uncropped images are presented in S2 Fig). An increase in the intensity of a slow-migrating band, which has been reported as phosphorylated Cx43, was observed in phorbol-12-myristate-13-acetate and epidermal growth factor (PMA+EGF) treated cells (positive control; Fig 5B). Treatment with 50 μM FNZ for 4 h also significantly increased the intensity of slow-migrating bands in the biotinylated samples (156.6 ± 9.2%; Fig 5B), indicating that FNZ increases Cx43 phosphorylation on the cell surface. No significant changes in total Cx43 levels were observed on the cell surface following FNZ treatment (79.5 ± 18.7%; Fig 5C).
Protein kinase C (PKC) is not involved in GJIC inhibition by FNZ
To investigate whether PKC is involved in GJIC inhibition by FNZ, I-YFP GJIC assays were conducted with the pan-PKC inhibitor, chelerythrine. A 1:4 mixture of LN215-YFPQL and LN215-SLC26A4 cells were treated with vehicle, 50 μM FNZ, or 50 μM FNZ together with 5 μM chelerythrine for 4 h. Chelerythrine did not antagonize FNZ-induced GJIC inhibition (50 μM FNZ, 26.6 ± 1.7%; 50 μM FNZ plus 5 μM chelerythrine, 27.9 ± 1.2%; Fig 6).
Effects of drugs with pharmacological properties similar to FNZ on GJIC
FNZ is a class IV calcium antagonist  with other moderate actions including dopamine D2 , histamine H1 , and 5-HT  receptor blocking activities. To investigate whether these pharmacological actions of FNZ are related to GJIC inhibition, several drugs, including calcium channel blockers, D2 antagonists, H1 blockers, and 5-HT antagonists, were used to treat LN215 cells at a concentration of 50 μM for 4 h prior to conducting I-YFP GJIC assays.
Three calcium channel blockers, amlodipine (87.4 ± 1.7%), verapamil (106.8 ± 1.5%), and diltiazem (104.9 ± 2.0%), did not block GJIC (Fig 7A) under the same treatment conditions as FNZ (14.2 ± 2.4%). None of the D2 antagonists (sulpiride, 101.3 ± 0.9%; domperidone, 101.6 ± 1.3%; and eticlopride hydrochloride, 104.2 ± 0.2%) significantly inhibited GJIC (Fig 7B). Similarly, no potent FNZ-like inhibition of GJIC was observed in cells treated with the ten H1 blockers or ten 5-HT antagonists (Fig 7C and 7D).
Cinnarizine is a drug with a pharmacodynamic profile similar to FNZ , lacking only two fluorine atoms present on the piperazine of FNZ (Fig 8A). In contrast to FNZ (4.2 ± 1.5%), cinnarizine (98.0 ± 2.5%) did not inhibit GJIC under the same treatment conditions as FNZ (Fig 8B). FNZ has also been shown to bind and inhibit calmodulin. To examine whether calmodulin inhibition by FNZ mediated GJIC inhibition in LN215 cells, the effect of bifonazole, a calmodulin antagonist, on GJIC was measured. Treatment with 50 μM bifonazole for 4 h did not inhibit GJIC (83.7 ± 5.7%; Fig 8B).
FNZ-mediated GJIC inhibition is not attenuated by dopamine, histamine, or 5-HT
Next, we examined whether dopamine, histamine, or 5-HT are involved in FNZ-induced GJIC inhibition. I-YFP GJIC assays were conducted in cells incubated with 50 μM FNZ alone, or together with 100 μM dopamine, 100 μM histamine, or 100 μM 5-HT for 4 h. FNZ treatment together with dopamine (6.1 ± 0.3%), histamine (5.4 ± 0.2%), or 5-HT (7.1 ± 0.2%) did not interfere with FNZ-induced GJIC inhibition and showed GJIC activities similar to cells treated with FNZ alone (4.9 ± 0.5%; Fig 9). These results suggest that GJIC inhibition by FNZ is not associated with its pharmacological effects on dopaminergic D2, histaminergic H1, or 5-HT receptors.
Effect of FNZ on [Ca2+]in
Elevation of [Ca2+]in has been shown to inhibit GJ activity . To investigate whether FNZ increased [Ca2+]in under the experimental conditions used in this study, a Fluo4 Ca2+ assay was conducted in LN215 cells treated with vehicle or 50 μM FNZ. The Fluo4 fluorescence of the cells was measured at 30-min intervals for 4 h. The fluorescence ratio of 50 μM FNZ-treated cells to vehicle-treated cells at each time point did not significantly change over 4 h (Fig 10A). Rapid changes in [Ca2+]in were also measured every 0.5 s for 100 s in LN215 cells treated with vehicle, 50 μM FNZ, or vehicle together with 100 μM ATP (positive control). As shown in Fig 10B, FNZ treatment did not cause a significant increase in [Ca2+]in, while treatment with vehicle together with 100 μM ATP elicited a strong increase in [Ca2+]in. These results indicate that FNZ inhibition of GJIC is not mediated by an increase in [Ca2+]in.
The present study demonstrated GJIC inhibition by FNZ, as well as experimental results related to its mechanism of action. In contrast to connexin modulators, such as mefloquine, flufenamic acid, and perhaps CBX, which directly bind to connexins and exhibit rapid kinetics , the onset of FNZ-induced GJIC inhibition and its reversal by washing were slow. These slow FNZ kinetics suggest that GJIC inhibition by FNZ is not due to its direct interaction with GJs, but rather is mediated by indirect mechanisms such as changes in (1) cellular or cell surface expression of connexin, (2) the phosphorylation status of connexin, and (3) cellular Ca2+ ion concentrations, which were evaluated in this study.
As only connexins on the cell surface can form GJs, we analyzed cell surface Cx43 in LN215 cells treated with FNZ. FNZ treatment significantly increased phosphorylated Cx43 without altering the total amount of Cx43 on the cell surface, as shown in Fig 5. Trafficking, assembly/disassembly, degradation, and gating of GJ channels are highly associated with phosphorylation events ;. The effects of connexin phosphorylation on GJIC vary according to the type of connexin kinase. Several kinases are involved in Cx43 phosphorylation. Phosphorylation of Cx43 by protein kinase A , AKT , and casein kinase 1  results in increased GJIC, whereas Cx43 phosphorylation by PKC ; and tyrosine kinase Src ; decrease GJIC. FNZ might induce Cx43 phosphorylation by PKC, Src, or other unknown kinases, thereby downregulating GJIC. PMA, a well-known GJ inhibitor (also known as 12-O-tetradecanoylphorbol-13-acetate [TPA]), activates PKC, which directly phosphorylates S368 sites on Cx43, resulting in decreased GJIC . Interestingly, the onset of PMA-induced GJIC inhibition was as slow as FNZ (S3 Fig), which supports the hypothesis that FNZ-induced GJ inhibition is due to increased phosphorylation of Cx43. However, a pan-PKC inhibitor, chelerythrine, did not antagonize FNZ-induced GJIC inhibition (Fig 6). This result suggests that kinases other than PKC might be involved in upregulation of Cx43 phosphorylation by FNZ.
An increase in [Ca2+]in inhibits GJs, possibly via the activation of calmodulin . In contrast, FNZ decreases [Ca2+]in  and has also been shown to bind and inhibit calmodulin , but block GJs. To investigate whether FNZ increases [Ca2+]in under the treatment conditions used in this study, resulting in GJIC inhibition, Fluo4 calcium assays were conducted during the FNZ treatment period. FNZ itself did not upregulate [Ca2+]in, as shown in Fig 10. Next, the effect of bifonazole, a calmodulin antagonist, on GJIC was examined to determine whether calmodulin inhibition by FNZ caused GJIC inhibition in LN215 cells; bifonazole did not inhibit GJIC (Fig 8B). These results suggest that GJIC inhibition by FNZ is not mediated by an alteration in cellular Ca2+ concentration or calmodulin inhibition.
FNZ has diverse pharmacological effects; it not only antagonizes the entry of calcium into cells , but also inhibits the functions of several neurotransmitter receptors including dopamine D2 , histamine H1 , and 5-HT receptors . To examine whether these previously established actions are related to GJIC inhibition by FNZ, we assessed the effects of chemicals that have pharmacological effects similar to FNZ on GJIC. None of the three calcium blockers, three D2 antagonists, ten H1 antagonists, or ten 5-HT antagonists potently inhibited GJIC in LN215 cells. Cinnarizine, which has a structure and pharmacodynamics profile similar to FNZ, did not inhibit GJIC (Fig 8B). Furthermore, FNZ inhibition of GJIC was not attenuated by co-treatment with a high concentration of dopamine, histamine, or 5-HT together with FNZ. Collectively, these data suggest that FNZ-mediated GJIC inhibition is not associated with its previously established pharmacological actions.
FNZ has been used for migraine prophylaxis and epilepsy adjuvant therapy . Interestingly, GJs are also associated with these two diseases. Initiation of cortical spreading depression (CSD), which triggers migraine auras and pain, is associated with astrocytes , in which Cx43 is predominantly expressed, as in LN215 ,. CSD depends on neuronal-glial communication mediated by GJs ;, which have been suggested as therapeutic targets for migraines. Tonabersat, a neuronal-glial GJ inhibitor, was is a candidate for migraine prevention . The beneficial effect of FNZ on migraines might be at least partially due to inhibition of Cx43, similar to tonabersat; however, this hypothesis needs to be further investigated. Connexin proteins and mRNAs are upregulated in temporal lobe neocortices , hippocampi ;, and cortices  of human epileptic tissues. Thus, GJ inhibitors have been suggested as potential antiepileptic agents ;. Agents that block GJs, such as carbenoxolone , quinine ;, meclofenamic acid ;, and tonabersat , have anticonvulsant effects . Thus, the anticonvulsant effects of FNZ might be due, at least in part, to GJ modulation.
1. Goodenough D a, Goliger J a, Paul DL. Connexins, connexons, and Intercellular Communication. Annu Rev Biochem. 1996;65: 475–502. doi: 10.1146/annurev.bi.65.070196.002355 8811187
2. Michela P, Velia V, Aldo P, Ada P. Role of connexin 43 in cardiovascular diseases. Eur J Pharmacol. Elsevier; 2015;768: 71–76. doi: 10.1016/j.ejphar.2015.10.030 26499977
3. Severs NJ, Coppen SR, Dupont E, Yeh HI, Ko YS, Matsushita T. Gap junction alterations in human cardiac disease. Cardiovascular Research. 2004. doi: 10.1016/j.cardiores.2003.12.007 15094356
4. Garbelli R, Frassoni C, Condorelli DF, Trovato Salinaro A, Musso N, Medici V, et al. Expression of connexin 43 in the human epileptic and drug-resistant cerebral cortex. Neurology. 2011;76: 895–902. doi: 10.1212/WNL.0b013e31820f2da6 21383325
5. Sarrouilhe D, Dejean C, Mesnil M. Involvement of gap junction channels in the pathophysiology of migraine with aura. Frontiers in Physiology. 2014. doi: 10.3389/fphys.2014.00078 24611055
6. Vinken M. Gap junctions and non-neoplastic liver disease. Journal of Hepatology. 2012. doi: 10.1016/j.jhep.2012.02.036 22609308
7. Kandyba EE, Hodgins MB, Martin PE. A murine living skin equivalent amenable to live-cell imaging: Analysis of the roles of connexins in the epidermis. J Invest Dermatol. 2008; doi: 10.1038/sj.jid.5701125 17960178
8. Akopian A, Kumar S, Ramakrishnan H, Roy K, Viswanathan S, Bloomfield SA. Targeting neuronal gap junctions in mouse retina offers neuroprotection in glaucoma. J Clin Invest. 2017;127: 2647–2661. doi: 10.1172/JCI91948 28604388
9. Pallares-Ruiz N, Blanchet P, Mondain M, Claustres M, Roux AF. A large deletion including most of GJB6 in recessive non syndromic deafness: A digenic effect? Eur J Hum Genet. 2002; doi: 10.1038/sj.ejhg.5200762 11896458
10. Bergoffen J, Scherer SS, Wang S, Oronzi Scott M, Bone LJ, Paul DL, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science (80-). 1993; doi: 10.1126/science.8266101 8266101
11. Paznekas WA, Boyadjiev SA, Shapiro RE, Daniels O, Wollnik B, Keegan CE, et al. Connexin 43 (GJA1) Mutations Cause the Pleiotropic Phenotype of Oculodentodigital Dysplasia. Am J Hum Genet. 2003; doi: 10.1086/346090 12457340
12. Paznekas WA, Karczeski B, Vermeer S, Lowry RB, Delatycki M, Laurence F, et al. GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Human Mutation. 2009. doi: 10.1002/humu.20958 19338053
13. Upham BL, Weis LM, Trosko JE. Modulated Gap Junctional Intercellular Communication as a Biomarker of PAH Epigenetic Toxicity: Structure-Function Relationship. Environ Health Perspect. 1998;106: 975. doi: 10.1289/ehp.98106s4975 9703481
14. U JET, Chang C, Upham B, Wilson M. Epigenetic toxicology as toxicant-induced changes in intracellular signalling leading to altered gap junctional intercellular communication. 1998;
15. Yamasaki H. Role of disrupted gap junctional intercellular communications in detection and characterization of carcinogens. Mutation Research—Reviews in Genetic Toxicology. 1996. doi: 10.1016/S0165-1110(96)90014-7
16. Vinken M, Doktorova T, Decrock E, Leybaert L, Vanhaecke T, Rogiers V. Gap junctional intercellular communication as a target for liver toxicity and carcinogenicity. 2009;44: 201–222. doi: 10.1080/10409230903061215 19635038
17. Lee JY, Choi EJ, Lee J. A new high-throughput screening-compatible gap junctional intercellular communication assay. BMC Biotechnol. BMC Biotechnology; 2015;15: 1–9. doi: 10.1186/s12896-015-0115-2 25636680
18. Yeo JH, Lee J. An Iodide-Yellow Fluorescent Protein-Gap Junction-Intercellular Communication Assay. J Vis Exp. 2019; doi: 10.3791/58966 30774121
19. Todd PA, Benfield P. Flunarizine. A reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs. 1989;
20. Asanuma M, Ogawa N, Haba K, Hirata H, Mori A. Calcium antagonist flunarizine hydrochloride affects striatal D2 dopamine receptors in the young adult and aged rat brain. Arch Gerontol Geriatr. 1991; doi: 10.1016/0167-4943(91)90049-V
21. Amini A, Heidari K, Kariman H, Taghizadeh M, Hatamabadi H, Shahrami A, et al. Histamine Antagonists for Treatment of Peripheral Vertigo: A Meta-Analysis. J Int Adv Otol. 2015; doi: 10.5152/iao.2015.1169 26381004
22. Zhu YH, Wang YL, Yang XP. Antagonistic effects of dipfluzine, flunarizine, and cinnarizine on 5-hydroxytryptamine-evoked contraction in pig basilar artery. Zhongguo Yao Li Xue Bao. 1996;
23. Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol. 2018; doi: 10.1111/ene.13621 29512871
24. Lee JY, Yoon SM, Choi EJ, Lee J. Terbinafine inhibits gap junctional intercellular communication. Toxicol Appl Pharmacol. 2016;307: 102–107. doi: 10.1016/j.taap.2016.07.022 27487578
25. Choi EJ, Yeo JH, Yoon SM, Lee J. Gambogic Acid and Its Analogs Inhibit Gap Junctional Intercellular Communication. 2018;9: 1–10. doi: 10.3389/fphar.2018.00814 30104974
26. Peracchia C. Chemical gating of gap junction channels: Roles of calcium, pH and calmodulin. Biochimica et Biophysica Acta—Biomembranes. 2004. doi: 10.1016/j.bbamem.2003.10.020 15033579
27. Verselis VK, Srinivas M. Connexin channel modulators and their mechanisms of action. Neuropharmacology. 2013. doi: 10.1016/j.neuropharm.2013.03.020 23597508
28. Rackauskas M, Neverauskas V, Skeberdis VA. Diversity and properties of connexin gap junction channels. Medicina (B Aires). 2010; doi: 1001-01 [pii]
29. Lampe PD, Lau AF. Regulation of gap junctions by phosphorylation of connexins. Arch Biochem Biophys. 2000; doi: 10.1006/abbi.2000.2131 11368307
30. Axelsen LN, Calloe K, Holstein-Rathlou N-H, Nielsen MS. Managing the complexity of communication: regulation of gap junctions by post-translational modification. Front Pharmacol. 2013; doi: 10.3389/fphar.2013.00130 24155720
31. Dunn CA, Lampe PD. Injury-triggered Akt phosphorylation of Cx43: a ZO-1-driven molecular switch that regulates gap junction size. J Cell Sci. 2014; doi: 10.1242/jcs.142497 24213533
32. Cooper CD, Lampe PD. Casein kinase 1 regulates connexin-43 gap junction assembly. J Biol Chem. 2002; doi: 10.1074/jbc.M209427200 12270943
33. Lampe PD, Lau AF. The effects of connexin phosphorylation on gap junctional communication. International Journal of Biochemistry and Cell Biology. 2004. doi: 10.1016/S1357-2725(03)00264-4 15109565
34. Solan JL, Lampe PD. Connexin43 in LA-25 Cells with Active v-src Is Phosphorylated on Y247, Y265, S262, S279/282, and S368 via Multiple Signaling Pathways. Cell Commun Adhes. 2008;15: 75–84. doi: 10.1080/15419060802014016 18649180
35. Geletu M, Trotman-Grant A, Raptis L. Mind the gap; Regulation of gap junctional, intercellular communication by the src oncogene product and its effectors. Anticancer Research. 2012. doi: 32/10/4245 [pii] 23060544
36. Lampe PD, TenBroek EM, Burt JM, Kurata WE, Johnson RG, Lau AF. Phosphorylation of connexin43 on serine368 by protein kinase C regulates gap junctional communication. J Cell Biol. 2000; doi: 10.1083/jcb.149.7.1503 10871288
37. Kubo K, Matsuda Y, Kase H, Yamada K. Inhibition of calmodulin-dependent cyclic nucleotide phosphodiesterase by flunarizine, a calcium-entry blocker. Biochem Biophys Res Commun. 1984;124: 315–321. doi: 10.1016/0006-291x(84)91555-9 6093793
38. Durham PL, Garrett FG. Neurological mechanisms of migraine: Potential of the gap-junction modulator tonabersat in prevention of migraine. Cephalalgia. 2009; doi: 10.1111/j.1468-2982.2009.01976.x 19723120
39. Dermietzel R, Hertberg EL, Kessler JA, Spray DC. Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J Neurosci. 1991; doi: 10.1523/JNEUROSCI.11-05-01421.1991
40. Giaume C, Fromaget C, El Aoumari A, Cordier J, Glowinski J, Grost D. Gap junctions in cultured astrocytes: Single-channel currents and characterization of channel-forming protein. Neuron. 1991; doi: 10.1016/0896-6273(91)90128-M
41. Silberstein SD. Tonabersat, a novel gap-junction modulator for the prevention of migraine. Cephalalgia. 2009; doi: 10.1111/j.1468-2982.2009.01973.x 19723123
42. Naus CCG, Bechberger JF, Paul DL. Gap junction gene expression in human seizure disorder. Exp Neurol. 1991; doi: 10.1016/0014-4886(91)90007-Y
43. Collignon F, Wetjen NM, Cohen-Gadol AA, Cascino GD, Parisi J, Meyer FB, et al. Altered expression of connexin subtypes in mesial temporal lobe epilepsy in humans. J Neurosurg. 2006; doi: 10.3171/jns.2006.105.1.77 16874892
44. Fonseca CG, Green CR, Nicholson LFB. Upregulation in astrocytic connexin 43 gap junction levels may exacerbate generalized seizures in mesial temporal lobe epilepsy. BRAIN Res. 2002; doi: 10.1016/S0006-8993(01)03289–9
45. Jahromi SS, Wentlandt K, Piran S, Carlen PL. Anticonvulsant actions of gap junctional blockers in an in vitro seizure model. J Neurophysiol. 2002; doi: 10.1152/jn.00801.2001
46. Jin MM, Chen Z. Role of gap junctions in epilepsy. Neuroscience Bulletin. 2011. doi: 10.1007/s12264-011-1944-1 22108816
47. Hosseinzadeh H, Nassiri Asl M. Anticonvulsant, sedative and muscle relaxant effects of carbenoxolone in mice. BMC Pharmacol. 2003; doi: 10.1186/1471-2210-3-3 12720572
48. Gajda Z, Szupera Z, Blazsó G, Szente M. Quinine, a blocker of neuronal Cx36 channels, suppresses seizure activity in rat neocortex in vivo. Epilepsia. 2005; doi: 10.1111/j.1528-1167.2005.00254.x 16190928
49. Nassiri-Asl M, Zamansoltani F, Torabinejad B. Antiepileptic effects of quinine in the pentylenetetrazole model of seizure. Seizure. 2009; doi: 10.1016/j.seizure.2008.08.002 18786839
50. Nilsen KE, Kelso ARC, Cock HR. Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy. Epilepsia. 2006; doi: 10.1111/j.1528-1167.2006.00540.x 16886980
51. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, et al. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005; doi: 10.1124/mol.104.007112 15598972
52. Parsons AA, Bingham S, Raval P, Read S, Thompson M, Upton N. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol. 2001; doi: 10.1038/sj.bjp.0703932 11264249
53. Manjarrez-Marmolejo J, Franco-Pérez J. Gap Junction Blockers: An Overview of their Effects on Induced Seizures in Animal Models. Curr Neuropharmacol. 2016;14: 759–771. doi: 10.2174/1570159X14666160603115942 27262601